Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

Rhea-AI Summary

Zealand Pharma announced a significant change in shareholding as major shareholder Polar Capital LLP reported holding 5.01% of total shares and voting rights. This notification was issued in compliance with the Danish Capital Markets Act. Zealand Pharma is a biotechnology company specializing in peptide-based medicines, with notable products including V-Go® and Zegalogue®. The press release highlights the company's advancements in clinical development and its integrated approach within the biotechnology sector.

Positive

• Polar Capital LLP now holds 5.01% of the shares and voting rights in Zealand Pharma.

Negative

• None.

Company announcement – No. 13 / 2022

Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

Polar Capital LLP has notified Zealand about a change of its total holding of shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, such that it now holds 5.01% of the shares and voting rights of Zealand.

Please see further details in the attached notification form.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. To support these two marketed products Zealand built a dedicated sales force in the United States and has established itself as a fully integrated biotechnology company. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations

Maeve Conneighton

Argot Partners

investors@zealandpharma.com

Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com

Attachment

• Zealand Pharma - Disclosure Form - 05.04.2022

FAQ

What is the recent shareholder update for Zealand Pharma (ZEAL)?

Polar Capital LLP has reported that it now holds 5.01% of the shares and voting rights in Zealand Pharma as of April 7, 2022.

What is Zealand Pharma known for?

Zealand Pharma is recognized for its focus on peptide-based medicines, including marketed products like V-Go® and Zegalogue®.

What does it mean for Polar Capital to hold 5.01% of Zealand Pharma (ZEAL)?

Holding 5.01% indicates that Polar Capital is a significant stakeholder, which could influence corporate decisions and strategies.

What is the implication of the shareholder notification under Danish law for Zealand Pharma?

The notification under the Danish Capital Markets Act ensures transparency about major shareholdings, which is essential for investor confidence and market integrity.